Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: Potential utility in diagnosis and management

Modern Pathology

Volumn 26, Issue 2, 2013, Pages 268-274

  Yemelyanova, Anna ^a   Gravitt, Patti E ^b,c   Ronnett, Brigitte M ^a   Rositch, Ann F ^c   Ogurtsova, Aleksandra ^a   Seidman, Jeffrey ^d   Roden, Richard B S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PERDANA UNIVERSITY   (Malaysia)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

biomarkers; capsid proteins; cervical cancer precursors; HPV; immunohistochemistry

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; CAPSID PROTEIN L2; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CANCER GRADING; CANCER GROWTH; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION;

ALPHAPAPILLOMAVIRUS; CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84873409253     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.156     Document Type: Article

References (33)

1. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113:18-25.
2. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
3. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678-1683.
4. Doorbar J, Cubie H. Molecular basis for advances in cervical screening. Mol Diagn 2005;9:129-142.
5. Middleton K, Peh W, Southern S, et al. Organization of human papillomavirus productive cycle during neo-plastic progression provides a basis for selection of diagnostic markers. J Virol 2003;77:10186-10201.
6. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007;23:297-313.
7. Buck CB, Cheng N, Thompson CD, et al. Arrangement of L2 within the papillomavirus capsid. J Virol 2008; 82:5190-5197.
8. Lee H, Lee KJ, Jung CK, et al. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol 2008;36:864-867.
9. Melsheimer P, Kaul S, Dobeck S, et al. Immunocyto-chemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 2003;47:124-128.
10. Lin Z, Yemelyanova AV, Gambhira R, et al. Expression pattern and subcellular localization of human papillo-mavirus minor capsid protein L2. Am J Pathol 2009;174:136-143.
11. Gravitt PE, Peyton C, Wheeler C, et al. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 2003; 112:23-33.
12. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods 2001;91:109-117.
13. Gambhira R, Karanam B, Jagu S, et al. A protective and broadly cross-neutralizing epitope of human papillo-mavirus L2. J Virol 2007;81:13927-13931.
14. Firzlaff JM, Kiviat NB, Beckmann AM, et al. Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology 1988;164:467-477.
15. Kurman RJ, Shah KH, Lancaster WD, et al. Immuno-peroxidase localization of papillomavirus antigens in cervical dysplasia and vulvar condylomas. Am J Obstet Gynecol 1981;140:931-935.
16. Kurman RJ, Jenson AB, Lancaster WD. Papillomavirus infection of the cervix. II. Relationship to intraepithe-lial neoplasia based on the presence of specific viral structural proteins. Am J Surg Pathol 1983;7:39-52.
17. Griesser H, Sander H, Hilfrich R, et al. Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol 2004;26:241-245.
18. Griesser H, Sander H, Walczak C, et al. HPV vaccine protein L1 predicts disease outcome of high-risk HPV+ early squamous dysplastic lesions. Am J Clin Pathol 2009;132:840-845.
19. Xiao W, Bian M, Ma L, et al. Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions. Acta Cytol 2010;54:661-667.
20. Yu L, Wang L, Zhong J, et al. Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol 2010;118:47-55.
21. Rauber D, Mehlhorn G, Fasching PA, et al. Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions. Eur J Obstet Gynecol Reprod Biol 2008;140:258-262.
22. Choi YS, Kang WD, Kim SM, et al. Human papilloma-virus L1 capsid protein and human papillomavirus type 16 as prognostic markers in cervical intraepithe-lial neoplasia 1. Int J Gynecol Cancer 2010;20:288-293.
23. Hilfrich R, Hariri J. Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol 2008;30:78-82.
24. Hoshikawa S, Sano T, Yoshida T, et al. Immunohisto-logical analysis of HPV L1 capsid protein and p16 protein in low-grade dysplastic lesions of the uterine cervix. Pathol Res Pract 2010;206:816-820.
25. Negri G, Bellisano G, Zannoni GF, et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008;32:1715-1720.
26. Huang MZ, Li HB, Nie XM, et al. An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions. Diagn Cytopathol 2010; 38:573-578.
27. Yoshida T, Sano T, Kanuma T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer 2008;114:83-88.
28. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005;11:4717-4723.
29. Auvinen E, Kujari H, Arstila P, et al. Expression of the L2 and E7 genes of the human papillomavirus type 16 in female genital dysplasias. Am J Pathol 1992;141: 1217-1224.
30. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34:1077-1087.
31. Brandsma JL, Sun Y, Lizardi PM, et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 2009;389: 100-107.
32. Sun C, Reimers LL, Burk RD. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 2011;121:59-63.
33. Turan T, Kalantari M, Calleja-Macias IE, et al. Methyla-tion of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression? Virology 2006; 349:175-183.